vs
德康医疗（DXCM）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是德康医疗的1.7倍（$2.1B vs $1.3B），德康医疗净利率更高（21.2% vs 15.8%，领先5.4%），德康医疗同比增速更快（21.6% vs 11.3%），过去两年德康医疗的营收复合增速更高（12.0% vs 10.5%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
DXCM vs ROP — 直观对比
营收规模更大
ROP
是对方的1.7倍
$1.3B
营收增速更快
DXCM
高出10.3%
11.3%
净利率更高
DXCM
高出5.4%
15.8%
两年增速更快
DXCM
近两年复合增速
10.5%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $2.1B |
| 净利润 | $267.3M | $331.0M |
| 毛利率 | 62.9% | 69.4% |
| 营业利润率 | 25.6% | 27.2% |
| 净利率 | 21.2% | 15.8% |
| 营收同比 | 21.6% | 11.3% |
| 净利润同比 | 153.6% | 842.6% |
| 每股收益（稀释后） | $0.67 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMROP
| Q1 26 | $1.3B | $2.1B | ||
| Q4 25 | $1.3B | $2.1B | ||
| Q3 25 | $1.2B | $2.0B | ||
| Q2 25 | $1.2B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.1B | $1.9B | ||
| Q3 24 | $994.2M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
净利润DXCMROP
| Q1 26 | $267.3M | $331.0M | ||
| Q4 25 | $267.3M | $428.4M | ||
| Q3 25 | $283.8M | $398.5M | ||
| Q2 25 | $179.8M | $378.3M | ||
| Q1 25 | $105.4M | $331.1M | ||
| Q4 24 | $151.7M | $462.3M | ||
| Q3 24 | $134.6M | $367.9M | ||
| Q2 24 | $143.5M | $337.1M |
毛利率DXCMROP
| Q1 26 | 62.9% | 69.4% | ||
| Q4 25 | 62.9% | 69.5% | ||
| Q3 25 | 60.5% | 69.5% | ||
| Q2 25 | 59.5% | 69.2% | ||
| Q1 25 | 56.9% | 68.7% | ||
| Q4 24 | 58.9% | 68.3% | ||
| Q3 24 | 59.7% | 69.2% | ||
| Q2 24 | 62.4% | 69.5% |
营业利润率DXCMROP
| Q1 26 | 25.6% | 27.2% | ||
| Q4 25 | 25.6% | 28.6% | ||
| Q3 25 | 20.1% | 28.4% | ||
| Q2 25 | 18.4% | 28.2% | ||
| Q1 25 | 12.9% | 27.9% | ||
| Q4 24 | 17.0% | 28.0% | ||
| Q3 24 | 15.3% | 28.1% | ||
| Q2 24 | 15.7% | 28.8% |
净利率DXCMROP
| Q1 26 | 21.2% | 15.8% | ||
| Q4 25 | 21.2% | 20.8% | ||
| Q3 25 | 23.5% | 19.8% | ||
| Q2 25 | 15.5% | 19.5% | ||
| Q1 25 | 10.2% | 17.6% | ||
| Q4 24 | 13.6% | 24.6% | ||
| Q3 24 | 13.5% | 20.8% | ||
| Q2 24 | 14.3% | 19.6% |
每股收益（稀释后）DXCMROP
| Q1 26 | $0.67 | $4.87 | ||
| Q4 25 | $0.67 | $3.97 | ||
| Q3 25 | $0.70 | $3.68 | ||
| Q2 25 | $0.45 | $3.49 | ||
| Q1 25 | $0.27 | $3.06 | ||
| Q4 24 | $0.37 | $4.29 | ||
| Q3 24 | $0.34 | $3.40 | ||
| Q2 24 | $0.35 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $382.9M |
| 总债务越低越好 | — | $9.7B |
| 股东权益账面价值 | $2.7B | $18.8B |
| 总资产 | $6.3B | $34.6B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资DXCMROP
| Q1 26 | $917.7M | $382.9M | ||
| Q4 25 | $917.7M | $297.4M | ||
| Q3 25 | $1.8B | $320.0M | ||
| Q2 25 | $1.2B | $242.4M | ||
| Q1 25 | $904.9M | $372.8M | ||
| Q4 24 | $606.1M | $188.2M | ||
| Q3 24 | $621.2M | $269.6M | ||
| Q2 24 | $939.2M | $251.5M |
总债务DXCMROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益DXCMROP
| Q1 26 | $2.7B | $18.8B | ||
| Q4 25 | $2.7B | $19.9B | ||
| Q3 25 | $2.7B | $20.0B | ||
| Q2 25 | $2.6B | $19.6B | ||
| Q1 25 | $2.3B | $19.2B | ||
| Q4 24 | $2.1B | $18.9B | ||
| Q3 24 | $2.0B | $18.5B | ||
| Q2 24 | $2.4B | $18.1B |
总资产DXCMROP
| Q1 26 | $6.3B | $34.6B | ||
| Q4 25 | $6.3B | $34.6B | ||
| Q3 25 | $7.5B | $34.6B | ||
| Q2 25 | $7.3B | $33.2B | ||
| Q1 25 | $6.8B | $31.4B | ||
| Q4 24 | $6.5B | $31.3B | ||
| Q3 24 | $6.4B | $31.6B | ||
| Q2 24 | $6.8B | $29.8B |
负债/权益比DXCMROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $507.0M |
| 自由现金流率自由现金流/营收 | — | 24.2% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXCMROP
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $738.0M | ||
| Q3 25 | $659.9M | $869.5M | ||
| Q2 25 | $303.0M | $404.1M | ||
| Q1 25 | $183.8M | $528.7M | ||
| Q4 24 | $301.4M | $722.2M | ||
| Q3 24 | $199.5M | $755.4M | ||
| Q2 24 | $279.4M | $384.1M |
自由现金流DXCMROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $192.1M | — | ||
| Q3 25 | $579.4M | — | ||
| Q2 25 | $208.9M | — | ||
| Q1 25 | $96.8M | — | ||
| Q4 24 | $176.8M | — | ||
| Q3 24 | $88.3M | — | ||
| Q2 24 | $213.3M | — |
自由现金流率DXCMROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 21.2% | — |
资本支出强度DXCMROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 6.6% | — |
现金转化率DXCMROP
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.72× | ||
| Q3 25 | 2.33× | 2.18× | ||
| Q2 25 | 1.69× | 1.07× | ||
| Q1 25 | 1.74× | 1.60× | ||
| Q4 24 | 1.99× | 1.56× | ||
| Q3 24 | 1.48× | 2.05× | ||
| Q2 24 | 1.95× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
